Hyperscale Human Health
Engineering the Future of Human Health and Transforming Medicine
May 4-7
2026
San Jose Convention Center
California, USA
May 5-8
2025
San Jose Convention Center
California, USA
About the event
The convergence of biotech, synthetic biology and AI is unlocking new frontiers in how we understand, treat, and prevent disease. From programmable biologics and RNA-based medicines to cell and gene therapies, the next era of healthcare is being built by innovators rethinking the entire therapeutic lifecycle.
Explore the breakthroughs transforming the “3Ds” of BioPharma—discovery, delivery, and development. Join trailblazing startups, global pharmaceutical leaders, and AI-first biotech platforms as they unveil next-generation tools, novel drug modalities, and scalable biomanufacturing solutions.
Human Bio also dives into the rapidly growing field of NeuroTech, where brain-computer interfaces, neuromodulation, and synthetic biology converge to unlock new treatments for neurological disorders and enhance human cognition.
This is where biology meets precision medicine—and where the future of human health is not just imagined, but engineered.
Top Sessions
1
-
Universal Immunity
What if immunity wasn’t just personal—it was programmable, portable, and universal? This session explores the cutting edge of immunological engineering, converging rapid-response vaccine platforms, AI-designed antibody libraries, and global health deployment systems to build a world no longer vulnerable to pandemics. From biofoundry-enabled vaccine design to distributed manufacturing and last-mile delivery, the conversation will examine the technological, clinical, and infrastructural shifts needed to create scalable immune resilience—across pathogens, across borders, and across populations. Join us as we reimagine the immune system not as a biological lottery, but as an engineered global asset.
[…]
2
-
AI-Driven Breakthroughs: Accelerating Drug Discovery and Genetic Medicine
In an era where AI is transforming medicine, drug discovery and genetic therapies are entering a new frontier. This session will explore how AI accelerates the development of innovative therapies, from optimizing molecular designs to enabling precise, tissue-specific genetic interventions. Discover how cutting-edge AI technologies are advancing therapeutic modalities, enhancing delivery systems, and unlocking the potential of personalized medicine. Join leading experts as they share groundbreaking insights into AI-driven innovation and its profound impact on the future of drug discovery and genetic medicine.
[…]
3
-
Innovation Meets Industry: How Startups Can Collaborate with Big Pharma
For startups in the BioPharma space, partnering with big pharma can be the key to scaling innovation and driving real-world impact. This session will bring together leaders from major pharmaceutical companies and successful startups to explore how to bridge the gap between groundbreaking ideas and industry execution. Learn about the key factors pharma companies look for in potential partners, best practices for collaboration" with "Innovation Meets Industry: How Startups Can Collaborate with Big Pharma"
[…]
4
-
Rewriting Life’s Code to Create New Polymers, Materials, and Medicines
In terrestrial life, DNA is copied to messenger RNA, and the 64 triplet codons in messenger RNAs are decoded – in the process of translation – to synthesize proteins. Cellular protein translation provides the ultimate paradigm for the synthesis of long polymers of defined sequence and composition but is commonly limited to polymerizing the 20 canonical amino acids. I will describe our progress towards the encoded synthesis of non-canonical biopolymers. These advances may form a basis for new classes of genetically encoded polymeric materials and medicines. To realize our goals, we are re-imagining some of the most conserved features of the cell; we have created new ribosomes, new aminoacyl-tRNA synthetase/tRNA pairs, and organisms with entirely synthetic genomes in which we have re-written the genetic code.
[…]
5
-
AI x RNA: Foundation Models for Rational Drug Design
Atomic AI operates at the convergence of artificial intelligence and RNA drug discovery — two revolutionary fields with significant potential, yet not without challenges. In developing an RNA foundation model for rational drug design, Atomic pioneered novel approaches to generate, process, and model RNA data (structure, function, and interactions) from first principles. This talk will reveal their methodological journey, critical insights gained, and identify persistent gaps in the broader field that currently constrain AI's capacity to transform drug discovery.
[…]
6
-
Hyperscale Biology: Designing Intelligence in Molecules
What happens when the architect behind the Transformer turns his focus to RNA and molecular design? Jakob Uszkoreit, Co-Founder of Inceptive and co-author of Attention is All You Need, joins John Cumbers, founder and CEO of SynBioBeta, for a conversation at the intersection of AI and biology. As synthetic biology enters the age of hyperscale—powered by generative models, molecular learning, and programmable therapeutics—Jakob shares his vision for reimagining intelligence not just in machines, but in the molecules that power life. Don’t miss this rare dialogue on the future of biodesign, computation, and the growing interface between synthetic biology and deep learning.
[…]
7
-
Unbound Biology: The Next Era of (Bio)Computing
The future of computing is being rewritten by biology. In this landmark session, Axios Managing Editor for Science & World, Alison Snyder, sits down with Stanford professor and synthetic biology pioneer Drew Endy and Microsoft CTO Kevin Scott to explore how programming living systems will transform the architecture of innovation. From designing cells with logic and memory to harnessing biological systems for sensing, computation, and decision-making, biology is becoming a powerful substrate for information processing. Join us for a forward-looking conversation on the convergence of synthetic biology and computing—and what it means for the future of technology, medicine, and planetary health.
[…]
8
-
Unbound Biology: Psychedelic Science Meets Breakthrough Biotech
The psychedelic renaissance is colliding with the frontiers of biotechnology, opening bold new pathways for healing, consciousness, and brain health. In this thought-provoking session, Gul Dolen, professor of behavioral and systems neuroscience at UC Berkeley, joins visionary investor Steve Jurvetson and Rick Doblin, founder of MAPS and pioneer of psychedelic-assisted therapy. Together, they’ll explore how synthetic biology, precision medicine, and neuroplasticity research are converging to unlock the therapeutic potential of psychedelics. From molecular design to regulatory breakthroughs, this conversation dives into the science, ethics, and future of reprogramming the mind.
[…]
9
-
The Neural Frontier: Pioneering Tomorrow's Brain Technologies
The stuff of science fiction is becoming reality! These scientist and entrepreneurs are tackling the next generation of brain connectomics, advanced brain-computer interfaces, neuromodulation, and stem cell replacement. These technologies aim to treat specific disorders today, but will enable a path for us to become cyborgs and live longer.
[…]
10
-
Strategic Alliances: How Pharma Thinks About Computational Drug Discovery Partnerships
This session explores how pharma companies approach and build effective partnerships with computational drug discovery firms. Industry experts will share insights on best practices for data sharing, strategies for navigating cultural challenges with biotech and startups, and the role of explainable AI in fostering trust. The discussion will also cover common mistakes companies make when approaching pharma and the considerations around using proprietary algorithms versus open-source models to advance drug discovery.
[…]
11
-
Next-Gen Medicine: AI-Powered Advances Reshaping Human Therapeutics
Dive into the cutting-edge today, not just the promises of tomorrow. This dynamic breakout session features biotech visionaries actively leveraging machine learning and AI to transform the engineering of human therapeutics. Hear firsthand from industry pioneers pushing the boundaries—from accelerating drug target discovery to streamlining clinical development pipelines. Learn how advanced analytics and big data are already enhancing personalized medicine, boosting clinical success rates, and rapidly reshaping the future landscape of healthcare. Don't miss this inside look at the real-world innovations redefining what's possible in therapeutic discovery and precision medicine.
[…]
1
-
Universal Immunity
What if immunity wasn’t just personal—it was programmable, portable, and universal? This session explores the cutting edge of immunological engineering, converging rapid-response vaccine platforms, AI-designed antibody libraries, and global health deployment systems to build a world no longer vulnerable to pandemics. From biofoundry-enabled vaccine design to distributed manufacturing and last-mile delivery, the conversation will examine the technological, clinical, and infrastructural shifts needed to create scalable immune resilience—across pathogens, across borders, and across populations. Join us as we reimagine the immune system not as a biological lottery, but as an engineered global asset.
[…]
2
-
AI-Driven Breakthroughs: Accelerating Drug Discovery and Genetic Medicine
In an era where AI is transforming medicine, drug discovery and genetic therapies are entering a new frontier. This session will explore how AI accelerates the development of innovative therapies, from optimizing molecular designs to enabling precise, tissue-specific genetic interventions. Discover how cutting-edge AI technologies are advancing therapeutic modalities, enhancing delivery systems, and unlocking the potential of personalized medicine. Join leading experts as they share groundbreaking insights into AI-driven innovation and its profound impact on the future of drug discovery and genetic medicine.
[…]
3
-
Innovation Meets Industry: How Startups Can Collaborate with Big Pharma
For startups in the BioPharma space, partnering with big pharma can be the key to scaling innovation and driving real-world impact. This session will bring together leaders from major pharmaceutical companies and successful startups to explore how to bridge the gap between groundbreaking ideas and industry execution. Learn about the key factors pharma companies look for in potential partners, best practices for collaboration" with "Innovation Meets Industry: How Startups Can Collaborate with Big Pharma"
[…]
4
-
Rewriting Life’s Code to Create New Polymers, Materials, and Medicines
In terrestrial life, DNA is copied to messenger RNA, and the 64 triplet codons in messenger RNAs are decoded – in the process of translation – to synthesize proteins. Cellular protein translation provides the ultimate paradigm for the synthesis of long polymers of defined sequence and composition but is commonly limited to polymerizing the 20 canonical amino acids. I will describe our progress towards the encoded synthesis of non-canonical biopolymers. These advances may form a basis for new classes of genetically encoded polymeric materials and medicines. To realize our goals, we are re-imagining some of the most conserved features of the cell; we have created new ribosomes, new aminoacyl-tRNA synthetase/tRNA pairs, and organisms with entirely synthetic genomes in which we have re-written the genetic code.
[…]
5
-
AI x RNA: Foundation Models for Rational Drug Design
Atomic AI operates at the convergence of artificial intelligence and RNA drug discovery — two revolutionary fields with significant potential, yet not without challenges. In developing an RNA foundation model for rational drug design, Atomic pioneered novel approaches to generate, process, and model RNA data (structure, function, and interactions) from first principles. This talk will reveal their methodological journey, critical insights gained, and identify persistent gaps in the broader field that currently constrain AI's capacity to transform drug discovery.
[…]
6
-
Hyperscale Biology: Designing Intelligence in Molecules
What happens when the architect behind the Transformer turns his focus to RNA and molecular design? Jakob Uszkoreit, Co-Founder of Inceptive and co-author of Attention is All You Need, joins John Cumbers, founder and CEO of SynBioBeta, for a conversation at the intersection of AI and biology. As synthetic biology enters the age of hyperscale—powered by generative models, molecular learning, and programmable therapeutics—Jakob shares his vision for reimagining intelligence not just in machines, but in the molecules that power life. Don’t miss this rare dialogue on the future of biodesign, computation, and the growing interface between synthetic biology and deep learning.
[…]
7
-
Unbound Biology: The Next Era of (Bio)Computing
The future of computing is being rewritten by biology. In this landmark session, Axios Managing Editor for Science & World, Alison Snyder, sits down with Stanford professor and synthetic biology pioneer Drew Endy and Microsoft CTO Kevin Scott to explore how programming living systems will transform the architecture of innovation. From designing cells with logic and memory to harnessing biological systems for sensing, computation, and decision-making, biology is becoming a powerful substrate for information processing. Join us for a forward-looking conversation on the convergence of synthetic biology and computing—and what it means for the future of technology, medicine, and planetary health.
[…]
8
-
Unbound Biology: Psychedelic Science Meets Breakthrough Biotech
The psychedelic renaissance is colliding with the frontiers of biotechnology, opening bold new pathways for healing, consciousness, and brain health. In this thought-provoking session, Gul Dolen, professor of behavioral and systems neuroscience at UC Berkeley, joins visionary investor Steve Jurvetson and Rick Doblin, founder of MAPS and pioneer of psychedelic-assisted therapy. Together, they’ll explore how synthetic biology, precision medicine, and neuroplasticity research are converging to unlock the therapeutic potential of psychedelics. From molecular design to regulatory breakthroughs, this conversation dives into the science, ethics, and future of reprogramming the mind.
[…]
9
-
The Neural Frontier: Pioneering Tomorrow's Brain Technologies
The stuff of science fiction is becoming reality! These scientist and entrepreneurs are tackling the next generation of brain connectomics, advanced brain-computer interfaces, neuromodulation, and stem cell replacement. These technologies aim to treat specific disorders today, but will enable a path for us to become cyborgs and live longer.
[…]
10
-
Strategic Alliances: How Pharma Thinks About Computational Drug Discovery Partnerships
This session explores how pharma companies approach and build effective partnerships with computational drug discovery firms. Industry experts will share insights on best practices for data sharing, strategies for navigating cultural challenges with biotech and startups, and the role of explainable AI in fostering trust. The discussion will also cover common mistakes companies make when approaching pharma and the considerations around using proprietary algorithms versus open-source models to advance drug discovery.
[…]
11
-
Next-Gen Medicine: AI-Powered Advances Reshaping Human Therapeutics
Dive into the cutting-edge today, not just the promises of tomorrow. This dynamic breakout session features biotech visionaries actively leveraging machine learning and AI to transform the engineering of human therapeutics. Hear firsthand from industry pioneers pushing the boundaries—from accelerating drug target discovery to streamlining clinical development pipelines. Learn how advanced analytics and big data are already enhancing personalized medicine, boosting clinical success rates, and rapidly reshaping the future landscape of healthcare. Don't miss this inside look at the real-world innovations redefining what's possible in therapeutic discovery and precision medicine.
[…]
1
-
Universal Immunity
What if immunity wasn’t just personal—it was programmable, portable, and universal? This session explores the cutting edge of immunological engineering, converging rapid-response vaccine platforms, AI-designed antibody libraries, and global health deployment systems to build a world no longer vulnerable to pandemics. From biofoundry-enabled vaccine design to distributed manufacturing and last-mile delivery, the conversation will examine the technological, clinical, and infrastructural shifts needed to create scalable immune resilience—across pathogens, across borders, and across populations. Join us as we reimagine the immune system not as a biological lottery, but as an engineered global asset.
[…]
2
-
AI-Driven Breakthroughs: Accelerating Drug Discovery and Genetic Medicine
In an era where AI is transforming medicine, drug discovery and genetic therapies are entering a new frontier. This session will explore how AI accelerates the development of innovative therapies, from optimizing molecular designs to enabling precise, tissue-specific genetic interventions. Discover how cutting-edge AI technologies are advancing therapeutic modalities, enhancing delivery systems, and unlocking the potential of personalized medicine. Join leading experts as they share groundbreaking insights into AI-driven innovation and its profound impact on the future of drug discovery and genetic medicine.
[…]
3
-
Innovation Meets Industry: How Startups Can Collaborate with Big Pharma
For startups in the BioPharma space, partnering with big pharma can be the key to scaling innovation and driving real-world impact. This session will bring together leaders from major pharmaceutical companies and successful startups to explore how to bridge the gap between groundbreaking ideas and industry execution. Learn about the key factors pharma companies look for in potential partners, best practices for collaboration" with "Innovation Meets Industry: How Startups Can Collaborate with Big Pharma"
[…]
4
-
Rewriting Life’s Code to Create New Polymers, Materials, and Medicines
In terrestrial life, DNA is copied to messenger RNA, and the 64 triplet codons in messenger RNAs are decoded – in the process of translation – to synthesize proteins. Cellular protein translation provides the ultimate paradigm for the synthesis of long polymers of defined sequence and composition but is commonly limited to polymerizing the 20 canonical amino acids. I will describe our progress towards the encoded synthesis of non-canonical biopolymers. These advances may form a basis for new classes of genetically encoded polymeric materials and medicines. To realize our goals, we are re-imagining some of the most conserved features of the cell; we have created new ribosomes, new aminoacyl-tRNA synthetase/tRNA pairs, and organisms with entirely synthetic genomes in which we have re-written the genetic code.
[…]
5
-
AI x RNA: Foundation Models for Rational Drug Design
Atomic AI operates at the convergence of artificial intelligence and RNA drug discovery — two revolutionary fields with significant potential, yet not without challenges. In developing an RNA foundation model for rational drug design, Atomic pioneered novel approaches to generate, process, and model RNA data (structure, function, and interactions) from first principles. This talk will reveal their methodological journey, critical insights gained, and identify persistent gaps in the broader field that currently constrain AI's capacity to transform drug discovery.
[…]
6
-
Hyperscale Biology: Designing Intelligence in Molecules
What happens when the architect behind the Transformer turns his focus to RNA and molecular design? Jakob Uszkoreit, Co-Founder of Inceptive and co-author of Attention is All You Need, joins John Cumbers, founder and CEO of SynBioBeta, for a conversation at the intersection of AI and biology. As synthetic biology enters the age of hyperscale—powered by generative models, molecular learning, and programmable therapeutics—Jakob shares his vision for reimagining intelligence not just in machines, but in the molecules that power life. Don’t miss this rare dialogue on the future of biodesign, computation, and the growing interface between synthetic biology and deep learning.
[…]
7
-
Unbound Biology: The Next Era of (Bio)Computing
The future of computing is being rewritten by biology. In this landmark session, Axios Managing Editor for Science & World, Alison Snyder, sits down with Stanford professor and synthetic biology pioneer Drew Endy and Microsoft CTO Kevin Scott to explore how programming living systems will transform the architecture of innovation. From designing cells with logic and memory to harnessing biological systems for sensing, computation, and decision-making, biology is becoming a powerful substrate for information processing. Join us for a forward-looking conversation on the convergence of synthetic biology and computing—and what it means for the future of technology, medicine, and planetary health.
[…]
8
-
Unbound Biology: Psychedelic Science Meets Breakthrough Biotech
The psychedelic renaissance is colliding with the frontiers of biotechnology, opening bold new pathways for healing, consciousness, and brain health. In this thought-provoking session, Gul Dolen, professor of behavioral and systems neuroscience at UC Berkeley, joins visionary investor Steve Jurvetson and Rick Doblin, founder of MAPS and pioneer of psychedelic-assisted therapy. Together, they’ll explore how synthetic biology, precision medicine, and neuroplasticity research are converging to unlock the therapeutic potential of psychedelics. From molecular design to regulatory breakthroughs, this conversation dives into the science, ethics, and future of reprogramming the mind.
[…]
9
-
The Neural Frontier: Pioneering Tomorrow's Brain Technologies
The stuff of science fiction is becoming reality! These scientist and entrepreneurs are tackling the next generation of brain connectomics, advanced brain-computer interfaces, neuromodulation, and stem cell replacement. These technologies aim to treat specific disorders today, but will enable a path for us to become cyborgs and live longer.
[…]
10
-
Strategic Alliances: How Pharma Thinks About Computational Drug Discovery Partnerships
This session explores how pharma companies approach and build effective partnerships with computational drug discovery firms. Industry experts will share insights on best practices for data sharing, strategies for navigating cultural challenges with biotech and startups, and the role of explainable AI in fostering trust. The discussion will also cover common mistakes companies make when approaching pharma and the considerations around using proprietary algorithms versus open-source models to advance drug discovery.
[…]
11
-
Next-Gen Medicine: AI-Powered Advances Reshaping Human Therapeutics
Dive into the cutting-edge today, not just the promises of tomorrow. This dynamic breakout session features biotech visionaries actively leveraging machine learning and AI to transform the engineering of human therapeutics. Hear firsthand from industry pioneers pushing the boundaries—from accelerating drug target discovery to streamlining clinical development pipelines. Learn how advanced analytics and big data are already enhancing personalized medicine, boosting clinical success rates, and rapidly reshaping the future landscape of healthcare. Don't miss this inside look at the real-world innovations redefining what's possible in therapeutic discovery and precision medicine.
[…]
It is really a technological cornucopia of new ideas and deployments of technology.
Chris Mason
Professor, Cornell University
It’s been a tremendously exciting conference for me, and very different to what I've been to before. Everyone's been extraordinary and generous with their time and ideas.
Drew Berry
Molecular Animator
Taking the SynBioBeta stage is an unmatched opportunity to share our work with the people who truly comprehend its enormity. It is the ultimate gathering for those at the forefront of the synthetic biology revolution.
Jodi Barrientos
CEO, Ribbon Bio
Every year there's more. There's more companies, there's more technologies, more applications of technologies.
Julianna LeMieux
Deputy Editor in Chief, GEN
This is an amazing conference, and a great chance to see a snapshot of the industry. It's a place where you can make a lot of little molecular interactions and collisions.
Kate Rubins
NASA Astronaut
I first came to SynBioBeta to learn more about the field. I stayed for the community. There is no better place to go learn and network.
Kristin Ellis
Partner, Lowercarbon Capital
An extraordinary and extraordinarily important conference, the only conference where I feel I learn a lot. SynBioBeta is my tribe!
Martine Rothblatt
Founder & CEO, United Therapeutics
A conference where every single person I met was a) brilliant b) had a new fresh tech idea and c) could have a huge positive transformational impact on the world and d) could communicate all this clearly and concisely.
Mary Lou Jepsen
Founder, Openwater
Easily my favorite and most stimulating conference. Every day I was pleasantly surprised by some nugget of insight. Coming from another field I was apprehensive, but the SynBioBeta community had a meaningful impact on me, and made me feel instantly welcome.
Mickey McManus
Senior Advisor & Executive Coach, BCG
I cannot think of a better place where I can find new talent each year to work with our teams.
Paul Stamets
Founder & Member, Fungi Perfecti
Pages
Other
Copyright SynBioBeta 2025
Pages
Other
Copyright SynBioBeta 2025
Pages
Other
Copyright SynBioBeta 2025
